Clinical Trial Update: Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD [Phase 4]

View source ↗

Summary

A randomized, open-label Phase 4 trial evaluating the inhibitory effect of evogliptin on progression of calcific aortic valve disease (CAVD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Calcific Aortic Valve Disease

Drugs mentioned

• Evogliptin (evogliptin)

Snippet

Sponsor: Asan Medical Center | Conditions: CAVD | Phase 4 | Status: UNKNOWN